ANNX
NASDAQ · Biotechnology
Annexon Inc
$5.11
-0.38 (-6.92%)
Open$5.45
Previous Close$5.49
Day High$5.62
Day Low$5.06
52W High$7.18
52W Low$1.29
Volume—
Avg Volume2.24M
Market Cap794.56M
P/E Ratio—
EPS$-1.38
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+698.6% upside
Current
$5.11
$5.11
Target
$40.81
$40.81
$23.52
$40.81 avg
$51.70
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 226.99M | 205.43M | 221.74M |
| Net Income | -28,556,645 | -21,219,491 | -26,718,856 |
| Profit Margin | -12.6% | -10.3% | -12.1% |
| EBITDA | -33,644,452 | -28,464,345 | -32,841,743 |
| Free Cash Flow | -13,512,889 | -15,079,405 | -14,899,369 |
| Rev Growth | +7.5% | +20.0% | +0.3% |
| Debt/Equity | 0.32 | 0.38 | 0.38 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |